IQVIA Pharma Deals
Half Year Review of 2018
The IQVIA Pharma Deals Half Year Review of 2018 shows that dealmaking in the life science industry remains dampened relative to same period in 2017. A significant factor contributing to this slowdown in deal activity is the buoyant financing market available to biopharmaceutical companies. Increasing inflow of venture capital has resulted in an all-time quarterly high of investment dollars in the first half of 2018, and investor sentiment towards public biotech companies is increasingly bullish, with biotech firms now more able to access the public markets early in their life cycle.
This White Paper provides an insightful overview of deal activity in the first half of 2018, as well as the outlook for deals for the remainder of 2018. Key information provided includes the following:
- Top M&A and partnership deals of H1 2018
- Deal activity rankings of the top pharmaceutical companies
- Deal activity by therapeutic area and development phase
- Deal value analysis of M&A, licensing and R&D deals
Download the full report to learn more.